Clinical Trial Update: ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ZACTIMA (vandetanib) plus docetaxel versus docetaxel alone in non-small cell lung cancer has completed with results posted in May 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Zactima (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Non-small Cell Lung Cancer, Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2011-05-24